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Treatment satisfaction data has been increasingly used as
an outcome measure for evaluating different therapeutic
regimens in recent years. However, published literature
focusing on the measurement of treatment satisfaction is
limited. OBJECTIVES: The purpose of this review is to
summarize different measures for treatment satisfaction
research from published literature. METHODS: English-
language studies published between 1989 to September
1999 were identified through a MEDLINE search. RE-
SULTS: Forty-nine studies on treatment satisfaction were
identified. The present review indicates a lack of stan-
dardization regarding the method of measuring treatment
satisfaction. The development of measurements for treat-
ment satisfaction was not well supported by a defined
conceptual model. Instruments were often short, self-
administered, and ad hoc measures. The limited number
of validated disease-specific measures for treatment satis-
faction included The Diabetes Treatment Satisfaction
Questionnaire, The Seattle Angina Questionnaire, and
The Pain Service Satisfaction Test for patients with chronic
pain. Applications of treatment satisfaction data were in
predicting drug utilization, patient acceptance and adher-
ence to treatment regimens, and monitoring patient needs
for improving the quality of health care. Likert-scaling
(dissatisfied to satisfied, strongly agree to strongly dis-
agree, poor to excellent) was the most frequently used
method in study measures of treatment satisfaction.
Common domains or questions that were included in
these measures were satisfaction with efficacy, feelings
about side effects, ease and convenience of therapy, de-
sire to continue therapy, cost of therapy, recommenda-
tion to others, and overall treatment satisfaction. The
studies of treatment satisfaction consistently suggested
that the treatment satisfaction score should be inter-
preted and evaluated in conjunction with clinical out-
comes and patient quality of life. CONCLUSION: Avail-
ability of standardized measures for treatment satisfaction
is still limited regardless of an increase in treatment
satisfaction research. The conceptualization of assess-
ments and the standardization of measures require fur-
ther development to increase their utility in outcomes re-
search.
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OBJECTIVES: Variability in unit costs is a common
problem in multicentre/multinational trials and poses
methodological challenges for health economists in per-
forming health economic evaluations. Up to now, signifi-
cant efforts have been made in providing appropriate
techniques to address this issue, such as sensitivity analy-
sis. However, there are drawbacks with these methods
such as variable selection bias. This research examines
the application of Monte-Carlo simulation to a multina-
tional trial dataset, and discusses its appropriateness as
an alternative technique in addressing the issue of unit
cost variability. METHODS: Monte-Carlo simulation
was incorporated with the bootstrapping technique to
derive estimates of the incremental cost-effectiveness ra-
tio (ICER) as well as its confidence interval using data
collected in a multinational phase III randomized con-
trolled trial of two alternative drug treatments for rheu-
matoid arthritis. In this trial, medical resources and unit
cost data were collected for 374 patients over a 108 week
period, enrolled at 56 centres in nine European countries.
The analysis was performed using CRYSTALBALL, @RISK,
MATLAB, and SAS using different distributional as-
sumptions (e.g. log-normal, log-logistic distributions) in
modelling unit cost variability. RESULTS: Estimates of
the ICER and its confidence interval were derived. This
information was then used to select the treatment regi-
men that was advantageous from a cost-effectiveness ar-
gument angle. CONCLUSIONS: Monte-Carlo simula-
tion represents a novel approach in incorporating unit
cost variability information into cost-effectiveness analy-
sis methodology. In this analysis, the technique assumes
that unit costs follow a log-normal distribution. As a rec-
ommendation, we suggest that the analyst should be sat-
isfied with the appropriate unit cost distributional as-
sumption when performing the analysis.
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BACKGROUND: A cohort of patients utilizing -ago-
nist medications was anonymously identified utilizing BC
Pharmacare data. To enable recruitment of a sample of
this cohort into a prospective study of The ‘Determinants
of Excessive -agonist Use,’ a recruiting strategy was de-
veloped to facilitate patient contact/enrollment without
violating confidentiality guidelines. METHODS: The
study cohort includes patients 19–50 yr. living in the
Greater Vancouver Regional District prescribed a short-
acting -agonist in 1998. Using encrypted personal
health numbers (PHNs), each patient’s primary prescrib-
ing physician will be identified, while remaining blind to
the patient’s identity. A random sample of eligible sub-
jects selected for enrollment into the study will then be
mixed (camouflaged ) ‘with encrypted PHNs of patients
not receiving a -agonist, identified from the Pharma-
care database, at a minimum ratio of one patient per
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physician. PHNs will be then unencrypted, patient ad-
dresses obtained, and recruitment letters mailed to pa-
tients (-agonist users and non-users) through their phy-
sician, who will be asked to forward the letters to
asthmatic patients identified from their practice. RE-
SULTS: 9420 subjects were identified as eligible for re-
cruitment; 7056, 1431, 653, and 280 in the low, interme-
diate, high and excessive use groups respectively, received
prescriptions from 3039 physicians. 500 patients will be
randomly selected by Pharmacare from the low, interme-
diate, and high use groups; all patients in the excessive
use group will be recruited. A primary prescribing physi-
cian will be identified for each patient, and at least one
non--agonist user will be selected for each physician.
Recruitment letters will be sent to 1780 patients, through
their physicians, in an effort to enroll 520 asthmatics.
CONCLUSIONS: This recruiting methodology has been
approved by two independent ethics committees. Utiliz-
ing anonymous patient data and camouflaged ‘sampling’
will ensure the protection of patient privacy while facili-
tating the recruitment of a representative, stratified sam-
ple of the study population.
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OBJECTIVE: To determine differences in statistical in-
ferences when evaluating drug therapy and other inter-
ventions with typical left censored (nonnegative) health
care cost data and different econometric models. METH-
ODS: One of the common problems confronting health
economists is the censored (nonnegative) nature of health
care cost data. Using simulated health care utilization
survey data we examined three alternative econometric
methods to model the effect of a therapeutic intervention
on patient ambulatory costs. The models included a sim-
ple Tobit model, a two-part model, and a Heckman two-
stage model. RESULTS: Results from the simple Tobit
suggested that the usage of institutional care had a signif-
icant negative effect on outpatient costs (672, P 
0.011). The results from a two-part model further found that
the negative effect was because patients who used institu-
tional care had lower likelihood of using outpatient care
(1.14, P  0.0025). Neither model found a significant
coefficient for the therapeutic intervention. A Heckman
two-stage model detected even more significant cost de-
terminants than the other two models. For example, it
showed that Medicaid eligibility had a significant nega-
tive effect (1.40, P  0.0014) on patient ambulatory cost,
and that the therapeutic intervention had a significant
negative effect (1.03, P  0.021) also. CONCLUSION:
In evaluation of patient ambulatory costs, the Heckman
two-stage model detected more explanatory variables with
significant effects than the simple Tobit model and two-
stage model. In contrast to the simpler econometric mod-
els, the Heckman two-stage model found that Medicaid
eligibility and the therapeutic intervention was associated
with reduced outpatient costs. This comparative evalua-
tion underscores the value of using appropriate econo-
metric methods when estimating the effects of drug ther-
apy or other medical interventions on treatment costs.
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In the analysis of cost-effectiveness data from a random-
ized controlled trial, a confidence interval (CI) for the in-
cremental cost-effectiveness ratio (ICER) is often pre-
sented to estimate the precision of the point estimate.
Researchers have proposed a variety of approaches to
construct such an interval. Fieller’s interval is known to
retain the coverage probability when the underlying dis-
tributions are normal. OBJECTIVE: To advocate the use
of Fieller’s interval and its extensions in estimating the CI
for the ICER. METHODS: Use empirical adjustment to
the modified signed log-likelihood ratio in situations
where the underlying distributions are known and non-
normal, and use the bootstrap-Fieller interval in situa-
tions where the underlying distributions are unknown.
RESULTS: These methods were applied to data from the
TRAndolapril Cardiac Evaluation (TRACE) study. CON-
CLUSION: These three likelihood-based methods are
recommended to estimate the CI for the ICER to retain
the coverage probability.
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